In his position, Squillante received material non-public information (“MNPI”) about various publicly traded companies. As an example, in February 2023, Squillante received MNPI about Praxis Precision Medicines, Inc. (“Praxis”), a clinical-stage biopharmaceutical company whose common stock traded on the NASDAQ. Between February 27 and March 2, 2023, Squillante “sold short” 38,086 shares of Praxis at an average price per share of approximately $3.04. Following the announcement, Squillante “covered” his short sale by purchasing 38,086 Praxis shares at an average price per share of approximately $1.82, making a profit of approximately $46,421. This matter was investigated by the Federal Bureau of Investigation with the assistance of the Securities and Exchange Commission.